Xuan Deng

机构：Capital Medical University, Beijing Anzhen Hospital · ORCID：0000-0002-4382-5665

发表论文 65 篇 · 总被引 2047 次 · h-index 17

代表论文

• LEAP-008: Lenvatinib Plus Pembrolizumab for Metastatic NSCLC That Has Progressed After an Anti–Programmed Cell Death Protein 1 or Anti–Programmed Cell Death Ligand 1 Plus Platinum Chemotherapy (2025 · Journal of Thoracic Oncology · 被引 18)
• The phase 3 INTerpath-002 study design: Individualized neoantigen therapy (INT) V940 (mRNA-4157) plus pembrolizumab vs placebo plus pembrolizumab for resected early-stage non–small-cell lung cancer (NSCLC). (2024 · Journal of Clinical Oncology · 被引 17)
• Identification of carotenoids and candidate genes shaping high pigment chili pepper variety (2023 · Scientia Horticulturae · 被引 15)
• Direct targeting of S100A9 with Icariin counteracted acetaminophen‑induced hepatotoxicity (2024 · International Immunopharmacology · 被引 14)
• Risk factors of osimertinib-related cardiotoxicity in non-small cell lung cancer (2024 · Frontiers in Oncology · 被引 10)
• 65O Phase III LEAP-008 study of lenvatinib plus pembrolizumab versus docetaxel for metastatic non-small cell lung cancer (NSCLC) that progressed on a PD-(L)1 inhibitor and platinum-containing chemotherapy (2023 · Immuno-Oncology Technology · 被引 10)